Trial Profile
Comparison of age-related macular degeneration treatments trials: Lucentis-avastin trial (CATT).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms CATT
- 01 Jul 2023 Results of an exploratory secondary analysis using data from this trial reporting retinal morphological outcomes or visual acuity data published in the British Journal of Ophthalmology
- 07 Jun 2017 Status changed from active, no longer recruiting to completed.
- 29 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Feb 2017.